Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China

Ming-Wu Zhang¹, Lin Zhou¹, Yu Zhang¹, Bin Chen¹, Ying Peng¹, Fei Wang¹, Zheng-Wei Liu¹, Xiao-Meng Wang²* and Song-Hua Chen¹*

Abstract

Background: The aim of this study was to assess the treatment outcomes of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) in Zhejiang, China and to evaluate possible risk factors associated with poor outcomes of M/XDR-TB.

Methods: Two-hundred-and-sixty-two patients having M/XDR-TB who received the diagnosis and treatment at nine referral hospitals from 1 January 2016 to 31 December 2016 in Zhejiang, China were included. All patients received second-line regimens recommended by WHO under the DOTS-Plus strategy.

Results: Among the 262 patients, the treatment success rate was 55.34% (n = 145) with 53.44% (n = 140) cured and 1.91% (n = 5) who completed treatment, 62 (23.66%) failed, 27 (10.31%) died, 16 (6.11%) defaulted and 12 (4.58%) transferred out. Forty (64.52%) of the 62 M/XDR-TB patients who failed treatment were due to adverse effects in the first 10 months of treatment. Eighteen patients (6.37%) had XDR-TB. Treatment failure was significantly higher among patients with XDR-TB at 50% than that among patients with non-XDR-TB at 21.72% (P = 0.006). Failure outcomes were associated with a baseline weight less than 50 kg (OR, 8.668; 95% CI 1.679–44.756; P = 0.010), age older than 60 years (OR, 9.053; 95% CI 1.606–51.027; P = 0.013), hemoptysis (OR, 8.928; 95% CI 1.048–76.923; P = 0.045), presence of cavitary diseases (OR, 10.204; 95% CI 2.032–52.631; P = 0.005), or treatment irregularity (OR, 47.619; 95% CI 5.025–500; P = 0.001).

Conclusion: Treatment outcomes for M/XDR-TB under the DOTS-Plus strategy in Zhejiang, China were favorable but still not ideal. Low body weight (< 50 kg), old age (> 60 years), severe symptoms of TB including cavitary disease, hemoptysis and irregular treatment were independent prognostic factors for failure outcomes in patients with M/XDR-TB.

Keywords: Prognostic factors, M/XDR-TB treatment, Treatment failure, Smear-negative, Adverse effects

Introduction

Drug-resistant tuberculosis (TB) remains a growing threat to public health and there were an estimated 1.2 million TB deaths among human immunodeficiency virus (HIV) -negative people and an additional 208,000 deaths among HIV-positive people in 2019 [1]. About half a million people developed rifampicin-resistant TB (RR-TB) worldwide in 2019 [2], of which 78% had multidrug-resistant TB (MDR-TB) [3]. A global total of 206 030 people with MDR/RR-TB were detected and almost 50% of the MDR-TB cases worldwide are estimated to occur in China and India [1]. Extensively drug-resistant tuberculosis (XDR-TB) is defined as MDR-TB with resistance to fluoroquinolone and at least one second-line injectable
agent (i.e. amikacin, kanamycin, and/or capreomycin). XDR-TB has been reported from more than 58 countries and is estimated to occur in up to 10% of MDR-TB patients [3].

A five-year study revealed that, of 9544 MTB isolates, there were 3376 (35.4%), 842 (8.8%) and 61 (0.64%) isolates identified as MDR-TB, XDR-TB and XDR-TB-Plus, respectively. The proportion of XDR-TB showed significant increase from 6.3% in 2011 to 9.1% in 2015[4]. In Zhejiang province China, MDR-TB showed a decreasing trend, while resistance to any first-line drugs showed an increasing trend, and 3.21%) and 21.28% MDR-TB cases were registered as new and previously treated cases, respectively. [5]. The prevalence of M/XDR-TB in Zhejiang Province underscores the continued need for effective treatment programs for drug-resistant TB.

This study aimed to investigate the outcomes of M/XDR-TB patients who were previously treated at provincial TB referral hospitals using the “DOTS-Plus” (a complementary DOTS-based strategy with provisions for treating multidrug-resistant tuberculosis) strategy, and to identify possible risk factors associated with poor treatment outcomes.

Methods
Study area, participants and procedures
The study area consisted of seven cities (Hangzhou, Huzhou, Shaoxing, Lishui, Quzhou, Jiaxing, and Wenzhou) including 39 counties with an urban area of about 19.2 million people in Zhejiang Province, China.

A total of 262 patients with culture-confirmed M/XDR-TB who accepted treatment at the 9 referral hospitals from 1 Jan 2016 to 31 Dec 2016 including 18 XDR-TB patients were included in this study.

The definitions of MDR-TB and XDR-TB as defined by the WHO were used in this study. Patients diagnosed with M/XDR-TB based on the drug susceptibility test (DST) results received a standardized or individual treatment regimen (WHO) [6].

Standard definitions for MDR-TB treatment outcome as defined by the suggested criteria of J.E. Farley, M. Ram et al. were used in this project [7]. A patient was considered successfully treated if consistently culture-negative for the final 12 months of treatment with completed treatment which is defined as “cured” or if unknown for bacteriological results but does not meet the definition for cure which is defined as “treatment completed”. An MDR-TB patient treatment interrupted for 2 or more consecutive months for any reason was defined as treatment default, while patient transferred to another unit with unknown treatment outcome was classified as “transfer out”. “Failure” is regarded as 2–5 positive cultures or 1 of any 3 positive cultures during the final 12 month of treatment.

Data collection
The treatment record of each patient was collected, e.g. information about symptoms of TB, baseline weight, and other characteristics (Table1). Results from the microbiology laboratory performed at the time of diagnosis of M/XDR-TB were reviewed and analyzed. All smear microscopy and culture on Lowenstein–Jensen media were positive. For all cases, isolates were sent for DST using the procedures of the provincial reference laboratories. All patients with M/XDR-TB isolates obtained prior to starting DOTS-Plus were sent to DST when the isolates were resistant to INH at 1 ug/ml and RMP at 40 ug/ml. In addition, these isolates sent to the laboratory for DST were tested for (resistance concentration): ethambutol (E), 2 ug/ml; kanamycin (Km), 30 ug/ml; streptomycin (S), 4 ug/ml; and ofloxacin (Ofx), 2 ug/ml.

Treatment of patients with M/XDR-TB
All cases were in residence in an area with DOTS-Plus implementation approved by the Green Light Committee (GLC) according to the Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis [8]. Two-hundred-and-thirty-five (89.69%) M/XDR-TB patients were treated under a standard regimen using the treatment protocol of M/XDR-TB and treatments of 27 (10.31%) were individualized by each referral hospital on the basis of DST results and adverse reactions. An injectable agent (including aminoglycoside or capreomycin) was used for a minimum of 6 months and at least 4 months past culture conversion. After the initial intensive treatment, the whole duration was 24 months.

Statistical analysis
The data were checked for completeness and consistency. Crude odds ratios (OR) and 95% confidence intervals (CI) were calculated using a stepwise logistic regression analysis with SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). The χ² or the Fisher’s exact test was used to determine the significant differences in frequencies of values in various groups where P < 0.05 was considered significant.

Results
Patients’ characteristics
In this study, 262 cases of M/XDR-TB were recruited for treatment, with 18 (6.87%) having XDR-TB. The median age of the patients with XDR-TB and Non-XDR-TB were 52.83 ± 14.95 years (range 29–77) and 46.07 ± 16.17 years (range 10–81), respectively. The majority of the patients (73.28%, n = 192) were male. The baseline characteristics of tuberculosis patients are shown in Table 1.
There was no significant difference between patients infected with MDR-TB and XDR-TB in terms of baseline weight, comorbidities, and laboratory findings. However, the presence of cavities at the time of diagnosis was more common in XDR-TB patients than those with Non-XDR-TB (72.22% vs 46.72%, \( P = 0.009 \)) (Table 1).

The resistance patterns are shown in Fig. 1; all patients were resistant to isoniazid and rifampicin. Among the second-line drugs, resistance to streptomycin (160, 61.07%) and ethambutol (107, 40.84%) was common; while resistance to ofloxacin (39, 14.89%) and kanamycin (19, 7.25%) was rare. Overall, 33.6% of the strains from the patients were resistant to at least one second-line anti-TB drug (ethambutol, streptomycin or ofloxacin). Multidrug resistance patterns were predominantly resistant to R/H, R/H/S/E and R/H/S at 27.86%, 24.81% and 24.05%, respectively (Fig. 2). Resistance to 5 or more drugs accounted for 9.54% of the multidrug resistance.

### Outcomes of the treatment

Among all patients, the treatment success rate was 55.34% (\( n = 145 \)) with 53.44% (\( n = 140 \)) cured and 1.91% (\( n = 5 \)) treatment completed. Treatment failure occurred in 62 patients (23.66%) and 27 (10.31%) died during treatment. A further 16 (6.11%) patients defaulted and 12 (4.58%) patients transferred out to other cities with unknown treatment outcome (Table 2). Of 140 cured patients, 136 (97%) converted to smear-negative in the first 6 months of treatment (\( \chi^2 = 113.540, P < 0.001 \)). Sixteen deaths (59.26% of the deaths) occurred in the first 6 months and 11 (40.74%) additional deaths occurred during the remaining 18 months of the treatment program.

The median duration of treatment success was 730.60 days (95% CI 717–731 days) for patients with XDR-TB and 730.65 days (95% CI 730.48–730.80 days) for patients with Non-XDR-TB.

### Table 1 Characteristic of 262 patients with M/XDR-TB enrolled in the DOTS-Plus program in Zhejiang, China between 1 January and 31 December 2016

| Characteristic                   | Total M/XDR-TB (\( n = 262 \)) | XDR-TB (\( n = 18 \)) | Non-XDR-TB (\( n = 244 \)) | \( \chi^2 \) | \( P \) |
|---------------------------------|---------------------------------|-----------------------|----------------------------|--------------|-------|
| Sex                             |                                 |                       |                            |              |       |
| Male                            | 192 (73.28)                     | 13                    | 179                        | 0.011        | 0.916 |
| Female                          | 70 (26.72)                      | 5                     | 65                         |              |       |
| Age                             |                                 |                       |                            |              |       |
| <45                             | 128 (48.85)                     | 5                     | 123                        | 4.776        | 0.092 |
| 45–59                           | 69 (26.34)                      | 5                     | 64                         |              |       |
| ≥60                             | 65 (24.81)                      | 8                     | 57                         |              |       |
| Occupation*                     |                                 |                       |                            |              |       |
| Farmer                          | 147 (56.11)                     | 10                    | 137                        | 2.054        | 0.152 |
| Others                          | 115 (43.89)                     | 8                     | 107                        |              |       |
| Family register*                |                                 |                       |                            |              |       |
| Resident                        | 124 (47.33)                     | 8                     | 116                        | 0.064        | 0.800 |
| Floating                        | 138 (52.67)                     | 10                    | 128                        |              |       |
| Previous TB treatment           |                                 |                       |                            |              |       |
| No                              | 21 (8.02)                       | 0                     | 21                         | 1.684        | 0.194 |
| Yes                             | 241 (91.98)                     | 18                    | 223                        |              |       |
| TB symptoms                     |                                 |                       |                            |              |       |
| Hemoptysis                      | 181 (69.08)                     | 13                    | 168                        | 0.089        | 0.765 |
| Cavity                          | 127 (48.47)                     | 13                    | 114                        | 6.752        | 0.009 |
| Hospitalized                    | 66 (25.19)                      | 2                     | 64                         | 2.033        | 0.154 |
| Comorbidities                   |                                 |                       |                            |              |       |
| Impaired renal function         | 82 (31.30)                      | 6                     | 76                         | 3.795        | 0.164 |
| Diabetes                        | 5 (1.91)                        | 0                     | 5                          | 3.433        | 0.150 |
| Liver disease                   | 2 (0.76)                        | 0                     | 2                          | 3.620        | 0.150 |

Data are No. (%)  
* Others including students and other occupations not investigated specifically  
* Permanent local residents were classified as “resident”, others as “Floating”
Fig. 1  Histogram of resistance and sensitivity for individual drugs, "resistant (R)" is marked in blue and "sensitive (S)" is marked in red.

Fig. 2  Percentage of resistance to each combination of drugs among the isolates from the 262 patients. XDR-TB is marked in blue and MDR-TB is marked in red.
Risk factors for treatment failure
The difference in treatment outcome was not statistically significant for gender, occupation, family register or other characteristics (Table 3).

Further, a total of 107 (40.84%) of the patients were resistant to ethambutol, 160 (61.07%) resistant to streptomycin, 19 (7.25%) resistant to kanamycin and 39 (14.89%) resistant to ofloxacin based on the DST results. Likewise, treatment outcomes did not indicate any significant difference between these drug-resistant patients (Table 3).

The treatment failure rate in XDR-TB group was 50% (n=9), significantly higher than the Non-XDR-TB group (21.72%, n=53, P=0.006; Table 2). Failure outcomes were more likely to occur if there was resistance to 6 or more drugs (R/H/Ox/Km/S/E) (P=0.014; Table 2).

In this study, 27 M/XDR-TB patients were treated with individualized regimens according to the DST results and other clinical symptoms. The overall success rate was much lower at 33.33% in comparison to 57.87% for those treated with standard regimen, partly due to that the death rate was much higher (29.63% versus 8.09%). The failure rate was similar between the two treatment regimens (33.33% versus 22.55%).

Further multivariate logistic regression analysis found that treatment failure was associated with baseline weight less than 50 kg (OR, 8.928; 95% CI 1.048–76.923; P=0.045), presence of cavitary disease (OR, 10.204; 95% CI 2.032–52.631; P=0.005), or treatment irregularity (OR, 47.619; 95% CI 5.025–500; P=0.001) (Table 3).

Forty (64.52%) of the 62 M/XDR-TB patients failed in the treatment due to adverse effects in the first 10 months of treatment. The median duration from the onset of treatment to fail was 92.5 days (95% CI 123.68–230.98 days). Twenty-two patients in the failure group had also been affected by other factors, such as irregular treatment, poor health condition and other reasons.

Twenty-seven patients (10.31%) died during treatment. Death during treatment was significantly associated with resistance to Ethambutol (P=0.045) or treatment irregularity (P=0.004) (Additional file 1: Table S1).

Adverse effects
One-hundred-and-twenty two patients (46.55%) experienced major clinically significant adverse effects caused by treatment, of which the most common was gastrointestinal (GI) upset (98, 37.40%), followed by hepatotoxicity (36, 13.74%), arthralgia or muscle pain (25, 9.54%) and allergic reaction (17, 6.49%). There were significantly more cases of allergic reaction in the Non-XDR-TB group (P=0.043). In our study, adverse drug effects occurred frequently in first 3 months of the treatment. The median duration of adverse effects was 92.50 days.

---

Table 2  Treatment outcomes and adverse reactions among patients with M/XDR-TB

| Treatment outcome | Total MDR-TB (N=262), n (%) | XDR-TB (N=18), n (%) | Non-XDR-TB (N=244), n (%) | χ² | P |
|-------------------|-----------------------------|---------------------|---------------------------|----|---|
| Treatment success (Cure, TC) | 145(55.34) | 6(33.33) | 139(56.97) | 3.789 | 0.052 |
| Cure | 140(53.44) | 6(33.33) | 134(54.92) | 2.331 | 0.126 |
| Completed | 5(1.91) | 0(0.00) | 5(2.05) | 0.078 | 0.779 |
| Failure | 62(23.66) | 9(50.00) | 53(21.72) | 7.420 | 0.006 |
| Death | 27(10.31) | 2(11.11) | 25(10.25) | 0.081 | 0.775 |
| Default | 16(6.11) | 0(0.00) | 16(6.56) | 0.373 | 0.541 |
| Transfer out | 12(4.58) | 1(5.56) | 11(4.51) | 0.143 | 0.704 |
| Adverse drug reactions | 122 (46.55) | 7(38.89) | 115(47.13) | 0.458 | 0.499 |
| GI upset* | 98(37.40) | 5(27.78) | 93(38.11) | 2.313 | 0.315 |
| Hepatotoxicity | 36(13.74) | 1(5.56) | 35(14.34) | 5.522 | 0.063 |
| Allergic reaction | 17(6.49) | 0(0.00) | 17(6.97) | 6.281 | 0.043 |
| Neurologic abnormalities | 5(1.91) | 0(0.00) | 5(2.05) | 5.434 | 0.066 |
| Mental disorder | 20(7.63) | 0(0.00) | 20(8.22) | 5.296 | 0.071 |
| Hematologic abnormalities | 20(7.63) | 0(0.00) | 20(8.22) | 5.296 | 0.071 |
| Electrolyte disturbances | 3(1.15) | 0(0.00) | 3(1.23) | 5.429 | 0.068 |
| Renal toxicity | 5(1.91) | 0(0.00) | 5(2.05) | 5.434 | 0.066 |
| Arthralgia or Courbature | 25(9.54) | 2(11.11) | 23(9.43) | 3.975 | 0.137 |
| Hypothyroidism | 10(3.82) | 1(5.56) | 9(3.69) | 5.049 | 0.080 |

* GI gastrointestinal
### Table 3  Factors associated with Treatment failure of 262 patients with M/XDR-TB

| Characteristic          | Treatment success | Treatment failure | Total | Univariate analysis | Multivariate analysis |
|-------------------------|-------------------|-------------------|-------|---------------------|-----------------------|
|                         | Cure, TC n(%)     | Failure n(%)      | N(%)  | OR (95% CI)         | P                     | OR (95% CI)         | P                     |
| Sex                     |                   |                   |       |                     |                       |                       |                       |
| Male                    | 105 54.69         | 42 21.88          | 142   | 73.28               | 1.25(0.656–2.383)     | 0.498                | 0.66(0.109–4.011)     | 0.652                |
| Female                  | 40 57.14          | 20 28.57          | 70    | 26.72               | 1                     |                       |                       |                       |
| Age                     |                   |                   |       |                     |                       |                       |                       |
| < 60 year               | 124 62.94         | 35 17.77          | 197   | 75.19               | 4.555(2.302–9.015)    | 0.000                | 9.053(1.606–51.027)   | 0.013                |
| ≥ 60 year               | 21 32.31          | 27 41.54          | 65    | 24.81               | 1                     |                       |                       |                       |
| Occupationa             |                   |                   |       |                     |                       |                       |                       |
| Farmer                  | 108 54.82         | 47 23.86          | 197   | 75.19               | 0.932(0.467–1.859)    | 0.841                | 1.343(0.262–6.898)    | 0.724                |
| Others                  | 37 56.92          | 15 23.08          | 52    | 24.81               | 1                     |                       |                       |                       |
| Family registerb        |                   |                   |       |                     |                       |                       |                       |
| Resident                | 62 50              | 38 30.65          | 124   | 47.33               | 0.472(0.257–0.866)    | 0.015                | 5.502(0.778–38.935)   | 0.088                |
| Floating                | 83 60.14          | 24 17.39          | 137   | 52.67               | 1                     |                       |                       |                       |
| Previous TB treatment   |                   |                   |       |                     |                       |                       |                       |
| No                      | 14 66.67          | 4 19.05           | 21    | 8.02                | 1.55(0.489–4.911)     | 0.457                | 2.033(0.113–36.662)   | 0.631                |
| Yes                     | 131 54.36         | 58 24.07          | 241   | 91.98               | 1                     |                       |                       |                       |
| Weight                  |                   |                   |       |                     |                       |                       |                       |
| < 50 kg                 | 19 44.19          | 16 37.21          | 43    | 16.41               | 2.824(1.198–6.657)    | 0.018                | 8.668(1.679–44.756)   | 0.01                 |
| ≥ 50 kg                 | 57 64.04          | 17 19.1           | 89    | 33.97               | 1                     |                       |                       |                       |
| TB symptoms             |                   |                   |       |                     |                       |                       |                       |
| Hemoptysis              |                   |                   |       |                     |                       |                       |                       |
| Yes                     | 105 58.01         | 38 20.99          | 143   | 69.08               | 0.603(0.322–1.129)    | 0.114                | 8.928(1.048–76.293)   | 0.045                |
| No                      | 40 49.38          | 24 29.63          | 81    | 30.92               | 1                     |                       |                       |                       |
| Cavitary                |                   |                   |       |                     |                       |                       |                       |
| Yes                     | 42 33.07          | 42 33.07          | 127   | 48.47               | 5.154(2.71–9.803)     | 0.000                | 10.204(2.032–52.361)  | 0.005                |
| No                      | 103 76.3          | 20 14.81          | 123   | 51.53               | 1                     |                       |                       |                       |
| Treatment               |                   |                   |       |                     |                       |                       |                       |
| Standard treatment      | 136 57.87         | 53 22.55          | 235   | 89.69               | 2.566(0.966–6.816)    | 0.059                | 0.447(0.027–7.449)    | 0.575                |
| Individualized treatment| 9 33.33           | 9 33.33           | 17    | 10.31               | 1                     |                       |                       |                       |
| Hospitalization         |                   |                   |       |                     |                       |                       |                       |
| No                      | 115 58.67         | 41 20.92          | 196   | 74.81               | 0.509(0.263–0.987)    | 0.046                | 0.365(0.066–2.009)    | 0.247                |
| Yes                     | 30 45.45          | 21 31.82          | 66    | 25.19               | 1                     |                       |                       |                       |
| Liver protection drugs  |                   |                   |       |                     |                       |                       |                       |
| Yes                     | 38 48.72          | 24 30.77          | 78    | 29.77               | 1.779(0.946–3.344)    | 0.074                | 1.764(0.935–142.857)  | 0.056                |
| No                      | 107 58.15         | 38 20.65          | 144   | 70.23               | 1                     |                       |                       |                       |
| First-line oral anti-TB agents | | | | | | | | |
| Ethambutol              |                   |                   |       |                     |                       |                       |                       |
| R                       | 58 54.21          | 25 23.36          | 103   | 40.84               | 0.987(0.538–1.811)    | 0.965                | 1.721(0.37–8.009)     | 0.489                |
| S                       | 87 56.13          | 37 23.87          | 155   | 59.16               | 1                     |                       |                       |                       |
| Injectable anti-TB agents | | | | | | | | |
| Streptomycin            |                   |                   |       |                     |                       |                       |                       |
| R                       | 92 57.15          | 34 21.25          | 166   | 61.07               | 1.43(0.782–2.614)     | 0.246                | 1.85(0.46–7.451)      | 0.387                |
| S                       | 53 51.96          | 28 27.45          | 102   | 38.93               | 1                     |                       |                       |                       |
| Kanamycin               |                   |                   |       |                     |                       |                       |                       |
| R                       | 7 36.84           | 9 47.37           | 17    | 7.25                | 0.299(0.106–0.843)    | 0.022                | 0.137(0.005–3.663)    | 0.236                |
| S                       | 138 56.79         | 53 21.81          | 243   | 92.75               | 1                     |                       |                       |                       |
| Fluoroquinolones        |                   |                   |       |                     |                       |                       |                       |
| Ofloxacin               | | | | | | | | |
Discussion

This study first analyzed the treatment outcomes of M/XDR-TB in Zhejiang, China. The overall success rate was 55.34%, with a success rate of 56.97% and 33.33% for patients with MDR-TB (excluding XDR-TB) and XDR-TB, respectively. The overall failure, defaulting and death rates were 23.66%, 6.11% and 10.31%, respectively, with a combined rate of 50.8% contributing to the poor outcome. We identified several risk factors contributing to this poor treatment outcome.

The overall success rate detected in our present study is higher than other reports from China [9, 10]. Liu Q et al. [9] reported a success rate of 50.7% for patients with MDR-TB and demonstrated that patients with pncA gene mutations, advanced age, and non-standard treatment had a significantly higher risk of poor treatment outcomes. Tang et al. [10] reported a success rate of only 40.95% in a cohort of 586 patients with 28.8% being XDR-TB patients. The higher proportion of XDR-TB patients may have contributed to the lower success rate in that study. Reports from other countries showed a success rate ranging from 38.6% to 74.0% [11–14].

A study Carried out in Brazil reported the proportion of unfavourable outcomes was 41.9% among MDR-TB and 81.5% among XDR-TB, which were higher than those in our present study [15]. The study also revealed that bilateral disease, HIV-positive, and comorbidities were associated with death and XDR-TB patients had a 4.7-fold higher odds of an unfavourable outcome [15]. In our present study, of the 140 cured patients, 136 (97%) of the patients converted to smear-negative in the first 6 months treatment course. However, a study conducted by Gao revealed that 24-week bedaquiline treatment combined with personalized anti-TB drug background regimens result in different initial sputum culture conversion rates, which were 84.6% for MDR-TB patients, 83.9% for pre-XDR-TB patients and 86.6% for XDR-TB patients [16]. The findings suggest that completing the initial treatment course of 6 months with injectable agents is critical for treatment success and also implies that any patient not cured during this first 6 months has a high chance of treatment failure and thus requires evaluation at the 6 months for treatment strategies.

In our study, 9 of the 27 M/XDR-TB patients treated with individualized regimens according to the DST results and other clinical symptoms were successful (33.33%) which was less favorable than those used standardized regimens with success rate of 57.87% (Table 3). However, there was no significant difference in the rate of treatment failure between standard and individualized treatments ($P=0.575$). A study conducted in Korea reported that delamanid-containing regimens resulted in a higher treatment success rate (81.6%) [17]. Another multi-center study revealed that bedaquiline-containing regimens in the treatment of MDR- and XDR-TB achieved a success of 71.3% (62.4% cured; 8.9% completed treatment). [18] Therefore, together with the introduction

### Table 3 (continued)

| Characteristic | Treatment success | Treatment failure | Total | Univariate analysis | Multivariate analysis |
|---------------|------------------|------------------|-------|-------------------|-------------------|
|               | Cure, TC (%)     | Failure (%)      | N (%) | OR (95% CI)       | P                 |
| R             | 14 (35.9)        | 14 (35.9)        | 39 (%)| 0.366(0.163–0.825) | 0.015             |
| S             | 131 (58.74)      | 48 (21.52)       | 223 (%)| 0.793(0.101–6.209) | 0.825             |
| Treatment regularity |               |                  |       |                   |                   |
| No            | 2 (7.14)         | 18 (64.29)       | 28 (%)| 0.693(0.364–1.319) |                   |
| Yes           | 143 (61.11)      | 44 (18.8)        | 234 (%)| 1.428(0.447–4.566) |                   |
| Resistant pattern |               |                  |       |                   |                   |
| R/H           | 38 (52.05)       | 21 (27.87)       | 73 (%)| 1.891(0.899–3.978) |                   |
| R/H/E         | 13 (61.90)       | 4 (19.05)        | 21 (%)| 1.427(0.686–2.969) |                   |
| R/H/S         | 42 (66.67)       | 11 (17.46)       | 63 (%)| 1.31(0.026–0.666)  | 0.014             |
| R/H/Ofx/Km/S/E| 3 (30.00)        | 6 (60.00)        | 10 (%)|                   |                   |

* Others including student and other occupation not investigated in specific

b Permanent local residence classified into “residence” otherwise “Floating”

c Treatment success including cured(Cure)and treatment completed(TC)

d OR adjusted odd ratio, CI confidence interval

* Hisoniazid, R rifampicin, E ethambutol, S streptomycin, Km kanamycin, Ofx ofloxacin. Analysis was done for patterns with at least 10 cases in total
of new anti-TB agents, the individualized treatment regimens might be effective to improve MDR-TB treatment outcome.

The primary factors associated with poor treatment outcomes in our study were age (>60 years), body weight (≤50 kg), with cavity disease or hemoptysis symptoms, and treatment irregularity. In recent study conducted in China indicated that genetic mutation of MTB strains was responsible for some unfavorable outcome [6, 19]. While another study performed in Brazil revealed that bilateral disease, HIV infection and comorbidities were associated with death [13]. These clinical signs are an indication of disease severity and are associated with diagnostic delays and prior long duration of treatment. Treatment irregularity as independent predictors of failure in M/XDR-TB patients was similarly reported by several studies [20, 21] underscoring the importance of patients receiving regular treatment. So the short-course treatment regimens according to drug-sensitivity test were conducted to provide more basis for MDR-TB treatment [22]. Even the study carried out among adolescent achieved treatment success rates of 88% and 83% with the 9-month regimen, and 90% and 75% with the 12-month regimen in adults and children/adolescents [23].

Previous studies suggest an association between resistance to certain anti-TB drugs and poor treatment outcomes in MDR-TB patients [24]. Accumulated studies confirmed that anti-TB-drug resistance always derives from genetic mutations in MTB strains, and MDR-TB was caused by a series of genetic mutations in MTB strains [25, 26]. Our study found no association of resistance to a single drug with treatment failure. However, resistance to 6 or more drugs was associated with treatment failure (P=0.014). The results mean that the more mutations in the MTB strains the more risk of resistances to anti-TB drugs. The molecular mechanisms of MDR-TB incidence indicate that the resistance to anti-TB drugs might be unable to be reversed, so developing new effective anti-TB agents was necessary for further treatment.

Besides drug resistance, adverse effects associated with second-line drugs have been reported as obstacles in the management of M/XDR-TB [27]. In our study, the majority of the 62 M/XDR-TB patients (64.52%) failed treatment were due to adverse effects. This finding advocates that adequate management of adverse effects shall improve treatment outcomes substantially.

The defaulting rate in this study is 6.11%. However, yet another study from China found that defaulting rate is 17% and a higher defaulting rate was also reported from Africa and India [28, 29]. Defaulted M/XDR-TB patients could potentially continue to infect others and are a threat to public health, just as Chisompola et al. reported that primary drug resistance remained the predominant type of transmission [30]. Therefore, reducing defaulting rate is critical to reduce M/XDR-TB spread.

Previous studies in Brazil and South Africa emphasize the roles of unemployment, socially disadvantaged patients, underweight, co-infection with HIV, alcohol and drug abuse and longer treatment duration in association with treatment default [31–34]. China has a massive floating population, and it was reported by Li et al. that the floating population and rural residents were considered high-risk groups for TB infection [35, 36]. This fact makes it especially challenging on treating M/XDR-TB case as risk of treatment default and transfer out is higher and far more difficult to manage in the floating population [35]. Further, treatment of M/XDR-TB is less effective, more toxic and more costly increases the risk of treatment default.

This study has several limitations. First, although a standard protocol and data collection format were used, data on patient’s height and BMI are poorly documented. Second, the number of XDR-TB patients in this study was small. The findings cannot fully represent treatment outcomes of XDR-TB in China. Third, we only had monitoring data for deaths and default in the studied patients. There was no record for the cause of death nor detailed information on default to assess actual reasons. Fourth, this study did not use standardized definitions of adverse effects, their diagnosis or their degree of severity. Despite these limitations, we believe this study provides an important evaluation of treatment outcomes of M/XDR-TB, especially as the first evaluation report in Zhejiang, China of countrywide DOTS-Plus implementation program.

**Conclusion**

In conclusion, this study found that the treatment outcome for M/XDR-TB was favorable with a success rate of 55.34% but still not ideal since outcomes for 40.8% patients were poor, consisting of 23.66% failure, 10.31% deaths and 6.11% defaults. Thus substantial effort is required to improve treatment outcomes. Several risk factors identified may be mitigated through clinical management, such as timely diagnosis, regular treatment and controlling adverse effects, and improving social welfare, such as better nutrition and treatment affordability. Our data show that the first 6 months is critical in reducing treatment failure and deaths. This study has important implications for clinical management of M/XDR-TB.

**Abbreviations**

H: Isoniazid; R: Rifampicin; E: Ethambutol; S: Streptomycin; Km: Kanamycin; Ofx: Ofloxacin.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40001-021-00502-0.

Additional file 1: Table S1. Risk factors for death among all M/XDR-TB patients registered for treatment in Zhejiang.

Acknowledgements

We appreciate the staff of the tuberculosis referral hospital in Zhejiang for their help in conducting the study.

Authors’ contributions

MZ, FW and ZL were responsible for data collection; LZ, YZ and BC were responsible for data analysis; YP, XW and SC responsible for study design and implementation. All authors read and approved the final manuscript.

Funding

The study was supported by the quality of life and its influencing factors of MDR-TB patient research (scientific research fund of Zhejiang Provincial De-partment of Health (2015KYA056), Tuberculosis epidemic and intervention mode research (2013ZX10003004) and Study on Molecular Mechanism and Risk Prediction of Pulmonary Tuberculosis Based on microRNA Regulation (2020keyan512).

Availability of data and materials

The supporting data can be acquired via correspondence author.

Declarations

Ethical approval and consent to participate

This study was approved by the ethics committee of Zhejiang provincial center for disease control and prevention. A signed consent by each participant was asked to provide.

Consent for publication

All the authors were consent for publication.

Competing interests

No conflict of interest to declare.

Received: 7 January 2021 Accepted: 17 March 2021

Published online: 03 April 2021

References

1. WHO. Global tuberculosis report 2020. WHO/HTM/TB/202011 2020.
2. Compendium of TB/COVID-19 studies. Geneva: World Health Organization; 2020 (https://www.who.int/teams/global-tuberculosis-programme/covid-19-compendium, accessed 29 July 2020).
3. Digital health for the End TB Strategy: an agenda for action (WHO/HTM/TB/2015.21). Geneva: WHO; 2015 (https://www.who.int/tb/publications/digitalhealth-TB-agenda/en/, accessed 29 July 2020).
4. Pang Y, Lu J, Huo F, Ma Y, Zhao L, Li Y, Liang G, Chu N, Gao M, Huang H. Prevalence and treatment outcome of extensively drug-resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PloS ONE. 2011;6:e20436.
5. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Geneva. 2014.
6. Liu Q, Yang D, Qu B, Martinez L, Ji Y, Song H, Li Z, Wang J. Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China. PloS Negl Trop Dis. 2021;15:e0009068.
7. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, Weyer K, Lancaster J, Van der Walt M. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PloS ONE. 2011;6:e20436.
8. WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Geneva. 2014.
9. Liu Q, Yang D, Qu B, Martinez L, Ji Y, Song H, Li Z, Wang J. Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China. PloS Negl Trop Dis. 2021;15:e0009068.
10. Tang S, Tan S, Yao L, Li F, Li L, Guo X, Li Y, Hao X, Li Y, Ding X, Zhang Z, Tong L, Huang J. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PloS ONE. 2013;8:e52943.
11. Piparva KG, Jansari G, Singh AP. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot. Perspect Clin Res. 2018;9:165–9.
12. Deba AI, Tank NRD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre Zhejiang. A four year retrospective study, Lung India: official organ of Indian Chest Society. 34 (2017) 522–526.13.
13. Patel SV, Nimavat KB, Alpesh PB, Shukla LK, Shrimgarpure KS, Mehta KG, Joshi CC. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: A prospective study. J Infect Public Health. 2016;9:478–84.
14. Hassane-Harouna S, Cherif GF, Orutuno-Gutierrez N, Cisse D, Camara LM, Diallo BD, Camara S, Bangoura AM, Lyeney L, Decroo T. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea. A retrospective cohort study. PLoS ONE. 2020;15:e0237355.
15. Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000–2016. PloS ONE. 2019;14:e0218299.
16. Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, Pei Y, Li G, Liu Y, Shu W, Fan L, Wu Q, Du J, Chen X, Tang F, Xiong Y, Li M, Cai Q, Jin L, Mei Z, Pang Y, Li L. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, (2020).
17. Mok J, Kang H, Koh WJ, Jhun BW, Yim JI, Kwak N, Lee T, Kang B, Jeon D. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea, The European respiratory journal, 54 (2019).
18. S.E. Borisov, K. Dheda, M. Enwerem, R. Romero Leyet, L. DAmbrosio, R. Bentis, G. Sotgiu, S. Tiberi, J.W. Affennar, A. Maryandyshev, E. Belibovski, S. Ganatra, A. Skrahina, O. Akkerman, A. Aleksa, R. Amale, J. Artseukhiev, J. Bruchfeld, J.A. Caminero, I. Carpena Martinez, J. Codecasa, M. Dalcolmo, J. Denholm, P. Douglas, R. Duarte, A. Esmail, M. Fadul, A. Filippov, L. Davies Forsman, M. Gaga, J.A. Garcia-Fuentes, J.M. Garcia-Garcia, G. Gualano, J. Jonsson, H. Kunst, J.S. Lau, R. Lazaro Maistra, J.L. Teran Troya, S. Manga, K. Manika, P. Gonzalez Montaner, J. Mullerpattan, S. Oelofse, M. Orelli, D.J. Palmero, F. Palmieri, A. Papalia, R. Papavasileiou, M.C. Payen, E. Pantoli, C. Bobalo Cordeiro, L. Saderi, T.D. Sadutschang, T. Sanukevich, V. Sokolovnikova, A. Spanevello, T. Topgyl, F. Toscanini, A.R. Tramontana, Z.F. Udvardia, P. Wiggiani, V. White, A. Zulma, G.B. Migliori, Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study, The European respiratory journal, 49 (2017).
19. Farley JE, Ram M, Pan W, et al. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PloS ONE. 2011;6:e20436.
20. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51:16–14.
21. Chen S, Hua P, Wang X, et al. Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study. Int J Infect Dis. 2013;17:e1116-1120.
22. Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis
(Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019;20:57.

23. Hatouna SH, Ortuno-Gutierrez N, Souleymane MB, Kizito W, Morou S, Boukary I, Zollo M, Benedetti G, Piubello A. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger. Int J Tuberculosis Lung Dis. 2019;23:625–30.

24. Tabarsi P, Chitsaz E, Baghaei P, et al. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Microb Drug Resist. 2010;16:81–6.

25. Matsui T, Pinhata JMW, Rangelo M, Brandao AP, Ferrazoli L, Leao SC, Vilanova-Cruz. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from Sao Paulo, Brazil. Memorias do Instituto Oswaldo Cruz. 2020;115:e200055.

26. Sayadi M, Zare H, Jamedar SA, Hashemy SI, Meshkat Z, Soleimanpour S, Hoffner S, Ghazvini K. Genotypic and phenotypic typification of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. BMC Infect Dis. 2020;20:390.

27. Van der Walt M, Lancaster J, Odendaal R, Davis JG, Shean K, Farley J. Serious treatment related adverse drug reactions amongst anti-retroviral naive MDR-TB patients. PloS ONE. 2013;8:e88817.

28. Marais E, Mlambo CK, Lewis JJ, et al.Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection. 2014;42:405–13.

29. Mishra B, Rockey WM, Gupta S, Srinivasa H, Muralidharan S. Multi-drug-resistant tuberculosis: the experience of an urban tertiary care hospital in South India using automated BACTEC 460 TB. Trop Doct. 2012;42:35–7.

30. Chisompola NK, Streicher EM, Muchemwa CMK, Warren RM, Sampson SL. Molecular epidemiology of drug resistant Mycobacterium tuberculosis in Africa: a systematic review. BMC Infect Dis. 2020;20:344.

31. Kigozi G, Heunis C, Chikobvu P, Botha S, van Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa, International journal of infectious diseases : IJID : official publication of the International Society for. Infect Dis. 2017;54:102.

32. Silva MR, Pereira JC, Costa RR, Dias JA, Guimarães MDC, Leite ICG. Drug addiction and alcoholism as predictors for tuberculosis treatment default in Brazil: a prospective cohort study. Epidemiol Infect. 2017;145:3516–24.

33. Priedeman Skiles M, Curtis SL, Angeles G, Mullen S, Senik T, Evaluating the impact of social support services on tuberculosis treatment default in Ukraine, PloS One, 13 (2018) e0199513.

34. Lackey B, Seas C, Van der Stuyft P, Otero L. Patient characteristics associated with tuberculosis treatment default: a cohort study in a high-incidence area of Lima, Peru. PloS ONE. 2015;10:e0128541.

35. Li X, Zhang H, Jiang S, et al. Active pulmonary tuberculosis case detection and treatment among floating population in China: an effective pilot. J Immigr Minor Health. 2010;12:811–5.

36. Li X, Li T, Tan S. Males, ages ≥45 years, businessperson, floating population, and rural residents may be considered high-risk groups for tuberculosis infection in Guangzhou, China: a review of 136,394 TB confirmed cases. Rev Inst Med Trop Sao Paulo. 2013;55:366–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.